T2 Biosystems Receives MedTech IGNITE Award

Cambridge, MA | Posted on October 11th, 2010

T2 Biosystems, Inc., a company developing the first point-of-care medical diagnostic products that enable rapid molecular and immunodiagnostic testing on a single instrument, today announced it has won the MedTECH IGNITE Innovative Technology Competition, an award that that honors a ground-breaking medical device innovation with outstanding market potential.

"We are honored to receive this award, which acknowledges the breakthrough potential of T2 Biosystems' revolutionary technology that eliminates extensive sample preparation for medical diagnostics," said John McDonough, CEO of T2 Biosystems. "This award recognizes the vision of T2's founders, as well as the innovation and scientific breakthroughs created by our world-class scientists and engineers."

T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven magnetic resonance (MR) technology. T2 Biosystems' diagnostics are poised to offer improved speed, accuracy and efficiency as well as portability to a broader range of settings including doctor's offices, homes and hospitals.

T2 Biosystems' technology has been validated in multiple published journal articles and has accurately analyzed viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.